메뉴 건너뛰기




Volumn 18, Issue 19, 2012, Pages 5163-5171

New strategies in acute myeloid leukemia: Redefining prognostic markers to guide therapy

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; DASATINIB; DAUNORUBICIN; DNA METHYLTRANSFERASE; ENTINOSTAT; HISTONE METHYLTRANSFERASE; IDARUBICIN; IMATINIB; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LESTAURTINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICRORNA; MIDOSTAURIN; MOCETINOSTAT; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; QUIZARTINIB; RAPAMYCIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SELUMETINIB; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VORINOSTAT;

EID: 84866911128     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0313     Document Type: Article
Times cited : (13)

References (61)
  • 1
    • 70349256226 scopus 로고    scopus 로고
    • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes
    • Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
    • (2009) Blood , vol.114 , pp. 937-951
    • Vardiman, J.W.1    Thiele, J.2    Arber, D.A.3    Brunning, R.D.4    Borowitz, M.J.5    Porwit, A.6
  • 4
    • 77449159028 scopus 로고    scopus 로고
    • Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet
    • Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453-74.
    • (2010) Blood , vol.115 , pp. 453-474
    • Dohner, H.1    Estey, E.H.2    Amadori, S.3    Appelbaum, F.R.4    Buchner, T.5    Burnett, A.K.6
  • 7
    • 77649096189 scopus 로고    scopus 로고
    • ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: A comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays
    • Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, Heinecke A, et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 2009;27:5031-8.
    • (2009) J Clin Oncol , vol.27 , pp. 5031-5038
    • Metzeler, K.H.1    Dufour, A.2    Benthaus, T.3    Hummel, M.4    Sauerland, M.C.5    Heinecke, A.6
  • 9
    • 80054119730 scopus 로고    scopus 로고
    • Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia
    • Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrozek K, Maharry K, et al. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood 2011;118:4188-98.
    • (2011) Blood , vol.118 , pp. 4188-4198
    • Schwind, S.1    Marcucci, G.2    Kohlschmidt, J.3    Radmacher, M.D.4    Mrozek, K.5    Maharry, K.6
  • 12
    • 77955134007 scopus 로고    scopus 로고
    • Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: Report from the International Microarray Innovations in Leukemia Study Group
    • Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Bene MC, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010;28:2529-37.
    • (2010) J Clin Oncol , vol.28 , pp. 2529-2537
    • Haferlach, T.1    Kohlmann, A.2    Wieczorek, L.3    Basso, G.4    Kronnie, G.T.5    Bene, M.C.6
  • 14
    • 84861999101 scopus 로고    scopus 로고
    • Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia
    • Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, et al. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 2012;26:1266-76.
    • (2012) Leukemia , vol.26 , pp. 1266-1276
    • Porter, C.C.1    Kim, J.2    Fosmire, S.3    Gearheart, C.M.4    Van Linden, A.5    Baturin, D.6
  • 15
    • 79251585678 scopus 로고    scopus 로고
    • Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study
    • Schwind S, Maharry K, Radmacher MD, Mrozek K, Holland KB, Margeson D, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:5257-64.
    • (2010) J Clin Oncol , vol.28 , pp. 5257-5264
    • Schwind, S.1    Maharry, K.2    Radmacher, M.D.3    Mrozek, K.4    Holland, K.B.5    Margeson, D.6
  • 16
    • 77952140672 scopus 로고    scopus 로고
    • Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
    • Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010;107:7473-8.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 7473-7478
    • Blum, W.1    Garzon, R.2    Klisovic, R.B.3    Schwind, S.4    Walker, A.5    Geyer, S.6
  • 17
    • 84858796262 scopus 로고    scopus 로고
    • IDH mutation impairs histone demethylation and results in a block to cell differentiation
    • Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483:474-8.
    • (2012) Nature , vol.483 , pp. 474-478
    • Lu, C.1    Ward, P.S.2    Kapoor, G.S.3    Rohle, D.4    Turcan, S.5    Abdel-Wahab, O.6
  • 18
    • 77955907891 scopus 로고    scopus 로고
    • IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication
    • Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28:3636-43.
    • (2010) J Clin Oncol , vol.28 , pp. 3636-3643
    • Paschka, P.1    Schlenk, R.F.2    Gaidzik, V.I.3    Habdank, M.4    Kronke, J.5    Bullinger, L.6
  • 19
    • 79954428737 scopus 로고    scopus 로고
    • TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study
    • Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011;29:1373-81.
    • (2011) J Clin Oncol , vol.29 , pp. 1373-1381
    • Metzeler, K.H.1    Maharry, K.2    Radmacher, M.D.3    Mrozek, K.4    Margeson, D.5    Becker, H.6
  • 21
    • 79953124734 scopus 로고    scopus 로고
    • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
    • Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011;117:3294-301.
    • (2011) Blood , vol.117 , pp. 3294-3301
    • Levis, M.1    Ravandi, F.2    Wang, E.S.3    Baer, M.R.4    Perl, A.5    Coutre, S.6
  • 22
    • 84878037713 scopus 로고    scopus 로고
    • A phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: Overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3
    • Apr 27. [Epub ahead of print]
    • Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, et al. A phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3. Leukemia 2012 Apr 27. [Epub ahead of print].
    • (2012) Leukemia
    • Stone, R.M.1    Fischer, T.2    Paquette, R.3    Schiller, G.4    Schiffer, C.A.5    Ehninger, G.6
  • 23
    • 70449475105 scopus 로고    scopus 로고
    • AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
    • Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009;114:2984-92.
    • (2009) Blood , vol.114 , pp. 2984-2992
    • Zarrinkar, P.P.1    Gunawardane, R.N.2    Cramer, M.D.3    Gardner, M.F.4    Brigham, D.5    Belli, B.6
  • 24
    • 77950421846 scopus 로고    scopus 로고
    • AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study
    • Abstract 636
    • Cortes J, Foran J, Ghirdaladze D, DeVetten MP, Zodelava M, Holman P, et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study. ASH Annual Meeting Abstracts 2009;114: Abstract 636.
    • ASH Annual Meeting Abstracts 2009 , vol.114
    • Cortes, J.1    Foran, J.2    Ghirdaladze, D.3    DeVetten, M.P.4    Zodelava, M.5    Holman, P.6
  • 25
    • 84866495319 scopus 로고    scopus 로고
    • A phase II open-label, AC220 monotherapy efficacy study in patients with refractory/relapsed Flt3-Itd positive acute myeloid leukemia: Updated interim results
    • Abstract 2576
    • Cortes JE, Perl AE, Smith CC, Kovacsovics T, Dombret H, Dohner H, et al. A phase II open-label, AC220 monotherapy efficacy study in patients with refractory/relapsed Flt3-Itd positive acute myeloid leukemia: updated interim results. ASH Annual Meeting Abstracts 2011; 118:Abstract 2576.
    • ASH Annual Meeting Abstracts 2011 , vol.118
    • Cortes, J.E.1    Perl, A.E.2    Smith, C.C.3    Kovacsovics, T.4    Dombret, H.5    Dohner, H.6
  • 26
    • 84857622836 scopus 로고    scopus 로고
    • Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: A retrospective analysis
    • Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G, Iori AP, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 2012;30:735-41.
    • (2012) J Clin Oncol , vol.30 , pp. 735-741
    • Brunet, S.1    Labopin, M.2    Esteve, J.3    Cornelissen, J.4    Socie, G.5    Iori, A.P.6
  • 28
    • 84878102263 scopus 로고    scopus 로고
    • Combination of a MEK inhibitor, AZD6244, and dual PI3K/mTOR inhibitor, NVP-BEZ235: An effective therapeutic strategy for acute myeloid leukemia
    • Abstract 3978
    • Liu H, Diaz-Flores E, Poire X, Odenike O, Koval G, Malnassy G, et al. Combination of a MEK inhibitor, AZD6244, and dual PI3K/mTOR inhibitor, NVP-BEZ235: an effective therapeutic strategy for acute myeloid leukemia. ASH Annual Meeting Abstracts 2010;116: Abstract 3978.
    • ASH Annual Meeting Abstracts 2010 , vol.116
    • Liu, H.1    Diaz-Flores, E.2    Poire, X.3    Odenike, O.4    Koval, G.5    Malnassy, G.6
  • 29
    • 0037513474 scopus 로고    scopus 로고
    • Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: Its significance as a prognostic variable [10]
    • DOI 10.1038/sj.leu.2402874
    • Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK, et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003;17:995-7. (Pubitemid 36626336)
    • (2003) Leukemia , vol.17 , Issue.5 , pp. 995-997
    • Min, Y.H.1    Eom, J.I.2    Cheong, J.W.3    Maeng, H.O.4    Kim, J.Y.5    Jeung, H.K.6    Lee, S.T.7    Lee, M.H.8    Hahn, J.S.9    Ko, Y.W.10
  • 30
    • 0042744837 scopus 로고    scopus 로고
    • Survival of acute myeloid leukemia cells requires PI3 kinase activation
    • DOI 10.1182/blood-2002-11-3429
    • Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003;102:972-80. (Pubitemid 36917792)
    • (2003) Blood , vol.102 , Issue.3 , pp. 972-980
    • Xu, Q.1    Simpson, S.-E.2    Scialla, T.J.3    Bagg, A.4    Carroll, M.5
  • 31
    • 70350726344 scopus 로고    scopus 로고
    • A phase i study of the mammalian target of rapamycin inhibitor sirolimus andMECchemotherapy in relapsed and refractory acute myelogenous leukemia
    • Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus andMECchemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009;15:6732-9.
    • (2009) Clin Cancer Res , vol.15 , pp. 6732-6739
    • Perl, A.E.1    Kasner, M.T.2    Tsai, D.E.3    Vogl, D.T.4    Loren, A.W.5    Schuster, S.J.6
  • 32
    • 79960289322 scopus 로고    scopus 로고
    • Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors
    • Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ, et al. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 2011;17:4378-88.
    • (2011) Clin Cancer Res , vol.17 , pp. 4378-4388
    • Altman, J.K.1    Sassano, A.2    Kaur, S.3    Glaser, H.4    Kroczynska, B.5    Redig, A.J.6
  • 33
    • 78349273297 scopus 로고    scopus 로고
    • Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia
    • Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010;16:5424-35.
    • (2010) Clin Cancer Res , vol.16 , pp. 5424-5435
    • Chapuis, N.1    Tamburini, J.2    Green, A.S.3    Vignon, C.4    Bardet, V.5    Neyret, A.6
  • 34
    • 84870726796 scopus 로고    scopus 로고
    • Final report of a phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance and presence of other comorbidities
    • Abstract 608
    • Garcia-Manero G, Estey EH, Jabbour E, Borthakur G, Kadia T, Naqvi K, et al. Final report of a phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance and presence of other comorbidities. ASH Annual Meeting Abstracts 2011;118: Abstract 608.
    • ASH Annual Meeting Abstracts 2011 , vol.118
    • Garcia-Manero, G.1    Estey, E.H.2    Jabbour, E.3    Borthakur, G.4    Kadia, T.5    Naqvi, K.6
  • 35
    • 84864011031 scopus 로고    scopus 로고
    • Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome
    • Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 2012;30:2204-10.
    • (2012) J Clin Oncol , vol.30 , pp. 2204-2210
    • Garcia-Manero, G.1    Tambaro, F.P.2    Bekele, N.B.3    Yang, H.4    Ravandi, F.5    Jabbour, E.6
  • 36
    • 34848865289 scopus 로고    scopus 로고
    • Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)
    • Abstract 1954
    • Garcia-Manero G, Yang AS, Giles F, Faderl S, Ravandi F, Cortes J, et al. Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). ASH Annual Meeting Abstracts 2006;108:Abstract 1954.
    • ASH Annual Meeting Abstracts 2006 , vol.108
    • Garcia-Manero, G.1    Yang, A.S.2    Giles, F.3    Faderl, S.4    Ravandi, F.5    Cortes, J.6
  • 37
    • 84866908835 scopus 로고    scopus 로고
    • Combination therapy with entinostat (MS-275) and GM-CSF to enhance differentiation in myeloid malignancies
    • Abstract 3312
    • Eunpi C, Matsui W, Kowalski J, Tsai H-L, Jones RJ, Smith BD. Combination therapy with entinostat (MS-275) and GM-CSF to enhance differentiation in myeloid malignancies. Blood 2010;116: Abstract 3312.
    • (2010) Blood , vol.116
    • Eunpi, C.1    Matsui, W.2    Kowalski, J.3    Tsai, H.-L.4    Jones, R.J.5    Smith, B.D.6
  • 40
    • 80055000824 scopus 로고    scopus 로고
    • RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
    • Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-8.
    • (2011) Nature , vol.478 , pp. 524-528
    • Zuber, J.1    Shi, J.2    Wang, E.3    Rappaport, A.R.4    Herrmann, H.5    Sison, E.A.6
  • 42
    • 77449149374 scopus 로고    scopus 로고
    • Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia
    • Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28:556-61.
    • (2010) J Clin Oncol , vol.28 , pp. 556-561
    • Cashen, A.F.1    Schiller, G.J.2    O'Donnell, M.R.3    DiPersio, J.F.4
  • 43
    • 80054984945 scopus 로고    scopus 로고
    • Inhibition ofBET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
    • Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition ofBET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478:529-33.
    • (2011) Nature , vol.478 , pp. 529-533
    • Dawson, M.A.1    Prinjha, R.K.2    Dittmann, A.3    Giotopoulos, G.4    Bantscheff, M.5    Chan, W.I.6
  • 44
    • 77449149373 scopus 로고    scopus 로고
    • Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia
    • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-9.
    • (2010) J Clin Oncol , vol.28 , pp. 562-569
    • Fenaux, P.1    Mufti, G.J.2    Hellstrom-Lindberg, E.3    Santini, V.4    Gattermann, N.5    Germing, U.6
  • 45
    • 84856802139 scopus 로고    scopus 로고
    • Azacitidine for the treatment of patients with acute myeloid leukemia: Report of 82 patients enrolled in an Italian Compassionate Program
    • Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012;118:1014-22.
    • (2012) Cancer , vol.118 , pp. 1014-1022
    • Maurillo, L.1    Venditti, A.2    Spagnoli, A.3    Gaidano, G.4    Ferrero, D.5    Oliva, E.6
  • 46
    • 84860772157 scopus 로고    scopus 로고
    • DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
    • Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 2012;26:1106-7.
    • (2012) Leukemia , vol.26 , pp. 1106-1107
    • Metzeler, K.H.1    Walker, A.2    Geyer, S.3    Garzon, R.4    Klisovic, R.B.5    Bloomfield, C.D.6
  • 47
    • 77950929054 scopus 로고    scopus 로고
    • Phase i study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
    • Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010;24:699-705.
    • (2010) Leukemia , vol.24 , pp. 699-705
    • Lancet, J.E.1    Gojo, I.2    Burton, M.3    Quinn, M.4    Tighe, S.M.5    Kersey, K.6
  • 48
    • 52649133274 scopus 로고    scopus 로고
    • HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells
    • Rao R, FiskusW, Yang Y, Lee P, Joshi R, Fernandez P, et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008;112:1886-93.
    • (2008) Blood , vol.112 , pp. 1886-1893
    • Rao, R.1    Fiskus, W.2    Yang, Y.3    Lee, P.4    Joshi, R.5    Fernandez, P.6
  • 51
    • 70349739288 scopus 로고    scopus 로고
    • Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma andmultiplemyeloma through a LSD1-mediated epigenetic mechanism
    • Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma andmultiplemyeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69:7347-56.
    • (2009) Cancer Res , vol.69 , pp. 7347-7356
    • Escoubet-Lozach, L.1    Lin, I.L.2    Jensen-Pergakes, K.3    Brady, H.A.4    Gandhi, A.K.5    Schafer, P.H.6
  • 52
    • 79951495012 scopus 로고    scopus 로고
    • A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
    • Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011;117:1828-33.
    • (2011) Blood , vol.117 , pp. 1828-1833
    • Fehniger, T.A.1    Uy, G.L.2    Trinkaus, K.3    Nelson, A.D.4    Demland, J.5    Abboud, C.N.6
  • 53
    • 77949350034 scopus 로고    scopus 로고
    • Identification of a primary target of thalidomide teratogenicity
    • Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010;327:1345-50.
    • (2010) Science , vol.327 , pp. 1345-1350
    • Ito, T.1    Ando, H.2    Suzuki, T.3    Ogura, T.4    Hotta, K.5    Imamura, Y.6
  • 55
    • 70350450612 scopus 로고    scopus 로고
    • Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia
    • Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009;27:4741-6.
    • (2009) J Clin Oncol , vol.27 , pp. 4741-4746
    • Schimmer, A.D.1    Estey, E.H.2    Borthakur, G.3    Carter, B.Z.4    Schiller, G.J.5    Tallman, M.S.6
  • 56
    • 67650410440 scopus 로고    scopus 로고
    • Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
    • Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009;113:6206-14.
    • (2009) Blood , vol.113 , pp. 6206-6214
    • Nervi, B.1    Ramirez, P.2    Rettig, M.P.3    Uy, G.L.4    Holt, M.S.5    Ritchey, J.K.6
  • 57
    • 84860349448 scopus 로고    scopus 로고
    • A phase I/II study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
    • Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, et al. A phase I/II study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012;119:3917-24.
    • (2012) Blood , vol.119 , pp. 3917-3924
    • Uy, G.L.1    Rettig, M.P.2    Motabi, I.H.3    McFarland, K.4    Trinkaus, K.M.5    Hladnik, L.M.6
  • 58
    • 77957711298 scopus 로고    scopus 로고
    • Preliminary results of Southwest Oncology Group Study S0106: An international intergroup Phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia
    • Abstract 790
    • Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup Phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. ASH Annual Meeting Abstracts 2009;114:Abstract 790.
    • ASH Annual Meeting Abstracts 2009 , vol.114
    • Petersdorf, S.1    Kopecky, K.2    Stuart, R.K.3    Larson, R.A.4    Nevill, T.J.5    Stenke, L.6
  • 59
    • 79952099282 scopus 로고    scopus 로고
    • Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial
    • Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011;29:369-77.
    • (2011) J Clin Oncol , vol.29 , pp. 369-377
    • Burnett, A.K.1    Hills, R.K.2    Milligan, D.3    Kjeldsen, L.4    Kell, J.5    Russell, N.H.6
  • 60
    • 84859911350 scopus 로고    scopus 로고
    • Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study
    • Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:1508-16.
    • (2012) Lancet , vol.379 , pp. 1508-1516
    • Castaigne, S.1    Pautas, C.2    Terre, C.3    Raffoux, E.4    Bordessoule, D.5    Bastie, J.N.6
  • 61
    • 84860121680 scopus 로고    scopus 로고
    • The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: Results of the UK NCRI AML16 randomized trial
    • Abstract 582
    • Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial. ASH Annual Meeting Abstracts 2011;118:Abstract 582.
    • ASH Annual Meeting Abstracts 2011 , vol.118
    • Burnett, A.K.1    Hills, R.K.2    Hunter, A.E.3    Milligan, D.4    Kell, W.J.5    Wheatley, K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.